Standalone point of care device. Single oral fluid sample, 16 substances screened, results in approximately 10 minutes. AS/NZS 4760:2019 compliant. Full digital chain of custody. Sold and deployed independently of HubX. Built for rail, transport, mining, defence, corrections, and other safety-regulated industries.
The EVEDA DtX kit delivers preliminary onsite screening across 16 substances of common workplace concern. One non-invasive saliva collection. Results in approximately 10 minutes. Designed to support workplace, healthcare, and law-enforcement compliance with drug and alcohol policies, and to integrate with confirmatory laboratory testing pathways where operator policy requires it.
AS/NZS 4760:2019 compliant oral fluid drug detection covering collection protocols, detection thresholds, approved methodologies, and cutoff levels.
Image-based strip-result capture removes manual transcription variance, locks results to a time-stamped digital record, and produces tamper-resistant documentation.
Secure cloud-based reporting and analytics dashboard. Centralised audit tracking for high-volume deployments. Role-based access. Encrypted at rest and in transit.
EVEDA operates under certified management systems including ISO 13485 (medical-device quality), ISO 9001 (quality management), and ISO 27701 (privacy information management).
Results available in approximately 10 minutes. Supports immediate fitness-for-duty determinations. Reduces downtime compared to lab-only workflows.
The DtX kit integrates with an EVEDA patient management app that streamlines testing workflows, record-keeping, chain of custody, and reporting. In-house compliance is workable without lab dependence.
One collection swab. Test parameters cover stimulants, opioids and synthetics, depressants, hallucinogens, dissociatives, and alcohol. Detection thresholds align with AS/NZS 4760:2019.
Sample type: oral fluid (saliva). Result time: approximately 10 minutes. Use case: preliminary onsite screening within DAMP (Drug and Alcohol Management Program) frameworks. Designed to integrate with confirmatory laboratory testing pathways where required under operator DAMPs.
Four feature pillars cover the working-day reality of safety-regulated environments: rapid decisions, accurate result capture, defensible documentation, and certified governance.
The DtX solution aligns with requirements under the Rail Safety National Law National Regulations (Drug and Alcohol Testing) Amendment Regulations 2024, and the AS/NZS 4760:2019 standard for oral fluid drug detection. The detail below summarises how each obligation maps to DtX capability.
Operators must conduct annual random testing using risk-based principles (minimum 25 percent in NSW context). DtX supports this through scalable onsite rapid testing, high-volume deployment capability, and centralised reporting dashboards for audit tracking.
Regulation 28(2)(b)(iiia) now explicitly references "an oral fluid analysis confirming the presence of a drug". DtX aligns through AS/NZS 4760:2019 compliant oral fluid screening, is designed to integrate with confirmatory laboratory testing pathways where required under operator DAMPs, and produces digitised preliminary result documentation.
The regulations address failure to provide samples, tampering with samples, and alteration of drug concentration prior to testing. DtX risk controls include image-verified strip reading, time-stamped digital capture, automated record locking, secure cloud audit trail, and chain of custody documentation functionality.
The DtX 16 parameter kit adheres to AS/NZS 4760:2019 for oral fluid drug detection, covering:
The EVEDA platform underpinning DtX is:
This supports operator obligations regarding confidential worker data handling, audit defensibility, and secure regulatory reporting.
DtX is built for environments where workplace fitness-for-duty is a legal, contractual, or regulatory obligation, and where lab-only workflows cost too much operational time. The capability is the same across sectors; the workflow integration is tailored per industry.
Onsite, AS/NZS 4760:2019 compliant testing that meets Rail Safety National Law obligations. Scalable to high-volume random testing programmes. Digital audit defensibility for DAMP reporting.
Onsite screening at remote and FIFO sites. Rapid, non-invasive collection. Centralised reporting across multiple deployment locations. Integrates with existing workplace health programmes.
Fitness-for-duty screening at training, posting, and operational tempo points. Time-stamped digital chain of custody. Encrypted reporting suitable for restricted environments.
Screening for a population with elevated substance-use prevalence in an environment with constrained lab access. Onsite, secure, dignified collection. Full audit trail.
Driver, operator, and contractor screening at depots and dispatch points. Rapid result turn-around supports same-shift decisions. Aligns with operator DAMPs.
Workplace and contracted-testing scenarios where rapid preliminary screening informs onward clinical or legal pathways. Designed to integrate with confirmatory laboratory testing where required.
A 16-panel oral fluid drug and alcohol screen.
Results in approximately 10 minutes.
Designed around AS/NZS 4760:2019 for oral fluid drug testing.
Yes, a digital chain of custody, with automated image reading and cloud reporting.
Safety-regulated industries, rail, mining, defence, transport, corrections and law enforcement.
Cloud reporting with enterprise-grade governance and patient-management integration.